AI-driven drug discovery demands a diverse skillset, spanning expertise in molecular biology, pharmacology, and machine learning. Arpeggio and its founders directly reflects this diversity.
- Joey Azofeifa — is an expert in AI and machine learning
- Tim Read — is a classically-trained molecular biologist, specializing in assay development
- Robin Dowell — is a tenured professor and leading researcher in bioinformatics, transcriptional regulation
- Daniel Weaver — is an industry leader in drug discovery with over 25 years of experience